Krystal Biotech Files DEF 14A, Details Executive Compensation
Ticker: KRYS · Form: DEF 14A · Filed: Apr 3, 2025 · CIK: 1711279
| Field | Detail |
|---|---|
| Company | Krystal Biotech, Inc. (KRYS) |
| Form Type | DEF 14A |
| Filed Date | Apr 3, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, executive-compensation, sec-filing
TL;DR
Krystal Biotech's 2025 DEF 14A is out, showing executive pay details and equity awards for 2024.
AI Summary
Krystal Biotech, Inc. filed its DEF 14A on April 3, 2025, detailing executive compensation and corporate governance for the fiscal year ending December 31, 2024. The filing includes information on equity awards granted to its principal executive officers and other employees, reflecting compensation structures and performance metrics relevant to the biotechnology sector.
Why It Matters
This filing provides insight into how Krystal Biotech compensates its top executives, which can signal management's focus and the company's financial health to investors.
Risk Assessment
Risk Level: medium — DEF 14A filings are routine disclosures, but the details on executive compensation and equity awards can impact investor sentiment and stock valuation.
Key Numbers
- 2024 — Fiscal Year (Reporting period for executive compensation details.)
- 2023 — Fiscal Year (Comparative data for equity awards.)
- 2022 — Fiscal Year (Comparative data for equity awards.)
- 2021 — Fiscal Year (Comparative data for equity awards.)
Key Players & Entities
- Krystal Biotech, Inc. (company) — Filer of the DEF 14A
- 20250403 (date) — Filing date of the DEF 14A
- 2100 WHARTON STREET SUITE 701 (address) — Company's business and mailing address
- PITTSBURGH, PA 15203 (address) — Company's business and mailing address
- 1231 (date) — Fiscal year end
FAQ
What is the primary purpose of a DEF 14A filing?
A DEF 14A filing, also known as a Definitive Proxy Statement, is filed by a company to solicit shareholder votes on important corporate matters, such as the election of directors and executive compensation.
When was Krystal Biotech's DEF 14A filed?
Krystal Biotech's DEF 14A was filed on April 3, 2025.
What fiscal year does this DEF 14A primarily cover?
This DEF 14A filing primarily covers the fiscal year ending December 31, 2024, with comparative data for prior years.
What is Krystal Biotech's Standard Industrial Classification (SIC) code?
Krystal Biotech's SIC code is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Where is Krystal Biotech, Inc. headquartered?
Krystal Biotech, Inc. is headquartered in Pittsburgh, PA, with its business and mailing address listed as 2100 Wharton Street, Suite 701, Pittsburgh, PA 15203.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 3, 2025 regarding Krystal Biotech, Inc. (KRYS).